Ocular trauma is an important cause of monocular blindness worldwide. Injury to the lens after blunt or penetrating trauma is common and can result in vision impairment. Selecting the most appropriate therapeutic approaches depends on factors such as patients' age, mechanism of trauma, and underlying clinical conditions. Early management, especially within childhood, is essential because of the difficulties involved in examination; anatomical variations; as well as accompanying intraocular inflammation, amblyopia, or vitreoretinal adhesions. The objective of this study was to provide a comprehensive review of the epidemiology and clinical management of traumatic cataract, highlighting the significance of accurate diagnosis and selection of the optimal therapeutic approach.
Background: To report the first case of bull’s eye maculopathy associated with veterinary niclosamide. Case presentation: A 27-year-old Iranian female presented with a history of reduced vision and photopsia since 3 years, after accidental ingestion of four boluses of veterinary niclosamide. Fundus examination showed atrophy in parafoveal retinal pigmentary epithelium, appearing as bilateral bull’s-eye maculopathy. Optical coherence tomography revealed disruption of the parafoveal ellipsoid zone and outer retinal thinning, appearing as a flying saucer sign. Electroretinography displayed decreased scotopic and photopic amplitudes with normal waveform in both eyes. The causality score was 4, showing “possible” retinopathy due to niclosamide according to Naranjo’s causality assessment algorithm. Based on clinical and ancillary findings, a diagnosis of niclosamide-induced maculopathy was made. Conclusion: Veterinary niclosamide is an anthelmintic drug that in higher doses could be detrimental to the human retina. Awareness about its side effects and appropriate drug labeling could prevent accidental toxicity.
Ocular surface tumors (OSTs) are rare but potentially life-threatening neoplasms encompassing entities such as ocular surface squamous neoplasia (OSSN), conjunctival melanoma, and lymphoma. Accurate diagnosis often requires expert ophthalmologists and pathologists, compounded by the reliance on advanced imaging modalities, with excisional biopsy being the gold standard. These limitations underscore the need for less invasive, accessible diagnostic approaches, where artificial intelligence (AI) holds significant promise. This review provides a comprehensive overview of AI advancements in OST management. It begins with definitions of AI and its key branches, followed by an examination of AI models applied to ophthalmic tumors using imaging data. Current developments in AI-related diagnostic tools for OSTs are discussed, highlighting their potential to enhance patient management, with classifications based on imaging modalities and specific OST types. Finally, the review addresses main challenges in AI implementation, including data limitations and ethical considerations, while outlining future directions to integrate AI into clinical ophthalmology practice. By bridging technological innovation with clinical needs, AI shows promise in OST diagnosis and management, ultimately improving outcomes in this challenging condition.
2 January 2026 in Journal of Oral and Maxillofacial Surgery